Munich
Germany
18
2025-09-11
The entities that hold a legal rights for patent applications filed by inventor Zugmaier Gerhard:
Gerhard Zugmaier from Munich, DE has applied for patents for these inventions. The list has both pending applications and granted patents:
SUBCUTANEOUS ADMINISTRATION OF CD19-BINDING T CELL ENGAGERS
#2 | 2025-05-15DOSING REGIMEN FOR BCMAx-CD3 ANTIBODIES CONSTRUCTS
#3 | 2024-04-04TREATMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA
#4 | 2023-07-27TREATMENT OF PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA
#5 | 2022-06-30MEANS AND METHODS FOR TREATING BURKITT LYMPHOMA OR LEUKEMIA
#6 | 2021-09-16DOSING REGIMEN FOR BCMA-CD3 BISPECIFIC ANTIBODIES
#7 | 2019-10-03Treatment of acute lymphoblastic leukemia
#8 | 2019-05-16Prevention of adverse effects caused by CD3 specific binding domains
#9 | 2019-05-02Administration of a bispecific construct binding to CD33 and CD3 for use in a method for the treatment of myeloid leukemia
#10 | 2017-11-16Anti-leukocyte adhesion for the mitigation of potential adverse events caused by CD3-specific binding domains
#11 | 2017-05-04Risk-stratification of B-precursor acute lymphoblastic leukemia patients
#12 | 2016-07-21Means and methods for treating DLBCL
#13 | 2015-03-12Dosage regimen for administering a CD19XCD3 bispecific antibody
#14 | 2014-08-14PPS for the prevention of potential adverse effects caused by CD3 specific binding domains
#15 | 2014-08-14Anti-leukocyte adhesion for the mitigation of potential adverse events caused by CD3-specific binding domains
#16 | 2013-10-31Means and methods for treating DLBCL
#17 | 2013-10-31Prevention of adverse effects caused by CD3 specific binding domains
#18 | 2012-12-27Dosage regimen for administering a CD19XCD3 bispecific antibody
1095362 ⎘